In plasma, the levels of CXCL16 measured using an ELISA were not different between RA-risk individuals with arthralgia (n = 19) and HC (n = 19, p = 0.110) (Fig. 4A) in Phase I cohort, whose clinical characteristics are shown in Table 1. This evidence concerns the gene CXCL16 and rheumatoid arthritis.